Intensive lifestyle intervention in type 2 diabetes and risk of incident coronary artery disease for the common haptoglobin phenotypes: the Look AHEAD study

被引:2
作者
Warren, Rachel A. [1 ,2 ]
Bancks, Michael P. [3 ]
Carew, Allie S. [1 ,2 ,4 ]
Levy, Andrew P. [5 ]
Sapp, John [1 ,2 ]
Bahnson, Judy [6 ]
Lewis, Cora E. [7 ]
Rimm, Eric B. [8 ,9 ]
Espeland, Mark A. [6 ,10 ]
Cahill, Leah E. [1 ,2 ,4 ]
机构
[1] Dalhousie Univ, Dept Med, Halifax, NS, Canada
[2] Nova Scotia Hlth Author, QEII Hlth Sci Ctr, Halifax, NS, Canada
[3] Wake Forest Univ, Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC USA
[4] Dalhousie Univ, Dept Community Hlth & Epidemiol, Halifax, NS, Canada
[5] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel
[6] Wake Forest Univ, Sch Med, Dept Biostat & Data Sci, Winston Salem, NC USA
[7] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA
[8] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA
[9] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
[10] Wake Forest Univ, Sch Med, Dept Internal Med Gerontol & Geriatr Med, Winston Salem, NC USA
关键词
Coronary artery disease; Epidemiology; Genetic association; Glycated hemoglobin; Haptoglobin phenotype; Type 2 diabetes mellitus; IN-VITRO; GENOTYPE; INDIVIDUALS; HEMOGLOBIN; POLYMORPHISM; PREVENTION;
D O I
10.1186/s12933-024-02164-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Intensive glycemic control reduced coronary artery disease (CAD) events among the Action to Control Cardiovascular Disease Risk in Diabetes (ACCORD) participants with the haptoglobin (Hp) 2-2 phenotype only. It remains unknown whether Hp phenotype modifies the effect of an intensive lifestyle intervention (ILI) on CAD in type 2 diabetes. Methods Haptoglobin phenotype was measured in 4542 samples from the Action for Health in Diabetes (Look AHEAD) study. Cox regression models assessed the effect of ILI (focused on weight loss from caloric restriction and physical activity) versus diabetes support and education (DSE) on CAD events in each phenotype group, and within pre-specified subgroups including race/ethnicity, sex, history of cardiovascular disease, diabetes medication use, and diabetes duration. Results 1590 (35%) participants had the Hp2-2 phenotype. The ILI did not lower glycated hemoglobin (%HbA1c) to < 6.5% in either phenotype, with a peak significant difference between treatment arms of 0.5% [non-Hp2-2] and 0.6% [Hp2-2]. The cumulative CAD incidence was 13.4% and 13.8% in the DSE arm and 12.2% and 13.6% in the ILI arm for non-Hp2-2 and Hp2-2 groups, respectively. Compared to DSE, the ILI was not associated with CAD among participants without (HR = 0.95, 95% CI 0.78-1.17) or with (0.89, 0.68-1.19) the Hp2-2 phenotype (p-interaction between Hp phenotype and ILI = 0.58). After Bonferroni correction, there were no significant results among any subgroups. Conclusions Hp phenotype did not modify the effect of the weight loss ILI on risk of CAD in Look AHEAD, potentially because it did not substantially impact glycemic control among participants with or without the Hp2-2 phenotype. Further research is needed to determine if these results are conclusive.
引用
收藏
页数:13
相关论文
共 34 条
[1]   8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2022 [J].
American Diabetes Association Professional Practice Committee* .
DIABETES CARE, 2022, 45 :S113-S124
[2]  
[Anonymous], 2013, N Engl J Med, V369, P145, DOI [DOI 10.1056/NEJMOA1212914, 10.1056/NEJMoa1212914.Cardiovascular, DOI 10.1056/NEJMOA1212914.CARDIOVASCULAR]
[3]   Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo [J].
Asleh, R ;
Guetta, J ;
Kalet-Litman, S ;
Miller-Lotan, R ;
Levy, AP .
CIRCULATION RESEARCH, 2005, 96 (04) :435-441
[4]   Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease [J].
Asleh, R ;
Marsh, S ;
Shilkrut, M ;
Binah, O ;
Guetta, J ;
Lejbkowicz, F ;
Enav, B ;
Shehadeh, N ;
Kanter, Y ;
Lache, O ;
Cohen, O ;
Levy, NS ;
Levy, AP .
CIRCULATION RESEARCH, 2003, 92 (11) :1193-1200
[5]   Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype [J].
Asleh, Rabea ;
Blum, Shany ;
Kalet-Litman, Shiri ;
Alshiek, Jonia ;
Miller-Lotan, Rachel ;
Asaf, Roy ;
Rock, Wasseem ;
Aviram, Michael ;
Milman, Uzi ;
Shapira, Chen ;
Abassi, Zaid ;
Levy, Andrew P. .
DIABETES, 2008, 57 (10) :2794-2800
[6]   Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo [J].
Asleh, Rabea ;
Miller-Lotan, Rachael ;
Aviram, Michael ;
Hayek, Tony ;
Yulish, Michael ;
Levy, Joanne E. ;
Miller, Benjamin ;
Blum, Shany ;
Milman, Uzi ;
Shapira, Chen ;
Levy, Andrew P. .
CIRCULATION RESEARCH, 2006, 99 (12) :1419-1425
[7]   Haptoglobin Phenotype Is Associated With High-Density Lipoprotein-Bound Hemoglobin Content and Coronary Endothelial Dysfunction in Patients With Mild Nonobstructive Coronary Artery Disease [J].
Asleh, Rabea ;
Levy, Andrew P. ;
Levy, Nina S. ;
Asleh, Ayat ;
Goldenstein, Hagit ;
Segol, Inbar ;
Gulati, Rajiv ;
Lerman, Lilach O. ;
Lerman, Amir .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2019, 39 (04) :774-786
[8]   Introduction to the Analysis of Survival Data in the Presence of Competing Risks [J].
Austin, Peter C. ;
Lee, Douglas S. ;
Fine, Jason P. .
CIRCULATION, 2016, 133 (06) :601-609
[9]   Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes [J].
Brancati, F ;
Charleston, J ;
Cheskin, L ;
Clark, J ;
DiGregorio-Celnik, D ;
Friedman-Donze, L ;
Rubin, R ;
Stewart, K ;
Bray, GA ;
DeLee, DG ;
Boss, KR ;
Greenway, FL ;
Lovejoy, JC ;
Ryan, DH ;
Williamson, DA ;
West, DS ;
DiLillo, V ;
Raczynski, JM ;
Lewis, CE ;
Oberman, A ;
Thomas, S ;
Nathan, DM ;
Horton, ES ;
Turgeon, H ;
Jackson, SD ;
Blackburn, GL ;
Delahanty, L ;
Steiner, B ;
Cagliero, E ;
Mantzoros, C ;
Hill, JO ;
Phillipp, J ;
Hamman, RF ;
Schwartz, R ;
Regensteiner, J ;
Van Dorsten, B ;
McDermott, MT ;
Dills, DG ;
Foreyt, JP ;
Reeves, RS ;
Pownell, HJ ;
Balasubramanyam, A ;
Jones, PH ;
Saad, MF ;
Jinagouda, S ;
Chiu, K ;
Morales, L ;
Ghazarian, S ;
Navarrete, G ;
Iqbal, N .
CONTROLLED CLINICAL TRIALS, 2003, 24 (05) :610-628
[10]   The Relationship Between Time-Varying Achieved HbA1c and Risk of Coronary Events Depends on Haptoglobin Phenotype Among White and Black ACCORD Participants [J].
Cahill, Leah E. ;
Warren, Rachel A. ;
Carew, Allie S. ;
Levy, Andrew P. ;
Ginsberg, Henry N. ;
Sapp, John ;
Lache, Orit ;
Rimm, Eric B. .
DIABETES CARE, 2023, 46 (11) :1941-1948